With four decades of experience in the biotechnology industry, Stewart Craig brings a wealth of expertise and leadership to his new role. For the past 30 years, Stewart has held executive positions focusing on the strategic development, implementation, and oversight of Chemistry, Manufacturing, and Controls (CMC), Technical Operations and Good Manufacturing Practice (GMP) infrastructures for cutting-edge cell and gene therapy enterprises.

Stewart’s journey in biotechnology has been marked by significant contributions to the field as he has played pivotal roles in spearheading the development, manufacturing, and clinical delivery of a diverse portfolio of biologics, including recombinant proteins, antibodies, cell therapies, viral vectors and gene-modified cell products. His expertise extends beyond operational realms, encompassing adept management of regulatory affairs across international jurisdictions, including the US, Canada, Switzerland, and Europe.

As the Co-founder and Principal Consultant at Broken Lance Biotech Consulting, Stewart Craig continues to be a guiding force within the biotech sector. His previous roles as Chief Technical Officer at jCyte, Inc. and Erytech Pharma, along with his tenure as Chief Manufacturing Officer at Orchard Therapeutics Ltd., Chief Operating Officer at Xcytye Therapies, Inc. and Senior Vice President of Technical Operations at Sangamo BioSciences, underscore his invaluable contributions to advancing innovative products into patient treatments.

“We are thrilled to welcome Stewart Craig to our Scientific Advisory Board,” expressed Jérôme Bédier, CEO of Flash BioSolutions. “His extensive experience and profound understanding of biotechnology will undoubtedly enrich our endeavors as we strive to pioneer transformative treatments for patients worldwide. Stewart’s participation will offer invaluable expertise to support the process validation needed to ensure the highest quality standards for our customers, particularly for our LentiCare® and FlashRNA® platforms.”

Stewart Craig added: “Joining the Scientific Advisory Board of Flash BioSolutions represents an exciting opportunity for me to contribute to the development of this innovator company within the CDMO sphere. I am deeply convinced that the future of biotechnology lies in dynamic collaborations between key players in the industry. Flash BioSolutions embodies this spirit of innovation and commitment to scientific excellence and quality in gene therapy. I’m driven by the desire to share my expertise and knowledge to help the company reach new heights in the manufacture and development of revolutionary treatments. Together, we can create a significant impact on patients’ lives and shape the future of medicine.”

As a distinguished member of Flash BioSolutions’s Scientific Advisory Board, Stewart Craig will provide invaluable strategic guidance and scientific acumen, further propelling the company’s mission to revolutionize gene therapy.

This rebranding effort is accompanied by the introduction of a dynamic visual identity, emblematic of its relentless pursuit of innovation and its stature as a premier provider of bespoke development and manufacturing solutions in the realm of gene delivery for cell and gene therapy, and immunization.

The decision to reemerge as Flash BioSolutions® signifies a pivotal juncture in the company’s journey, signifying its unwavering resolve to fortify its foothold in the global pharmaceutical outsourcing arena as an indomitable force.

“Our transition to Flash BioSolutions® epitomizes a pivotal evolutionary stride for our enterprise,” declares Jérôme Bédier, the CEO of Flash BioSolutions®. “Our rebranded identity and revitalized visual representation epitomize our steadfast commitment to excellence, operational prowess, and groundbreaking innovation. We take immense pride in our legacy as trailblazers in gene delivery for cell and gene therapy and vaccination, and eagerly anticipate furnishing our clientele with avant-garde solutions to cater to their burgeoning demands.”

The revamped visual identity of Flash BioSolutions® embodies a contemporary industrial aesthetic, emblematic of the company’s resilience, vigor, and pledge to deliver unrivaled quality and innovation. A comprehensive overhaul of the website, slated for launch on July 1, will culminate the identity revamp initiative, enhancing the sales outreach strategies.

Under the distinguished banner of Flash BioSolutions®, the company remains steadfast in its commitment to furnishing cutting-edge development and contract manufacturing services for DNA and RNA gene delivery. This rebranding endeavor aligns seamlessly with the company’s trajectory of expansion and global outreach to meet the escalating market exigencies.

This Pharmaceutical Establishment status provides Flash BioSolutions with additional regulatory authority and strengthens its ability to develop and deliver high quality products to its partners and customers. This step underlines Flash BioSolutions’ commitment to innovation and excellence.

One of Flash BioSolutions’ two flagship technologies, FlashRNA®, is a revolutionary RNA technology. Designed to be injected directly into humans, FlashRNA® opens up new perspectives in the treatment of genetic diseases, vaccines, cancers and other serious conditions. FlashRNA® technology promises to be an effective and innovative solution to major unmet medical needs.

« We are extremely proud to receive Pharmaceutical Establishment status » said CEO Jérôme Bédier. « This achievement demonstrates our commitment to excellence and reinforces our determination to deliver breakthrough therapies that could be game changers for our customers in the treatment of serious diseases. We look forward to working with our partners to realise the full potential of this FlashRNA® technology, which will be injected into humans as early as 2025. »

« We are convinced that this certification will reinforce our customers’ confidence in our ability to provide high-quality biomanufacturing solutions » added Virginie Jassin, Quality Director. « We would like to thank all our employees for their investment. Their collaboration has been essential in reaching this important milestone in the life of the company. »